Get the Stockscreener App
21.55
2.60%
0.545
Pre-market:
21.79
0.245
+1.14%
Enliven Therapeutics Inc stock is traded at $21.55, with a volume of 390.89K.
It is up +2.60% in the last 24 hours and up +13.34% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$21.00
Open:
$20.97
24h Volume:
390.89K
Relative Volume:
0.72
Market Cap:
$1.28B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-11.40
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
-0.76%
1M Performance:
+13.34%
6M Performance:
-3.34%
1Y Performance:
-9.13%
1-Day Range:
$20.57
$21.79
1-Week Range:
$19.57
$22.14
52-Week Range:
$13.30
$25.96
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.55 | 1.25B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - sharewise.com
Ready to Jump After Recent Trade: Enliven Therapeutics Inc (ELVN) - Setenews
Will Enliven Therapeutics Inc. stock keep outperforming rivals2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Is Enliven Therapeutics Inc. stock ready for breakout2025 Volume Leaders & Long-Term Growth Stock Strategies - Newser
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 8%Time to Sell? - MarketBeat
Geode Capital Management LLC Grows Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Franklin Resources Inc. Has $8.63 Million Stock Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Risks Report: Will Enliven Therapeutics Inc. stock benefit from AI adoption2025 Macro Impact & Smart Swing Trading Alerts - BỘ NỘI VỤ
Will Enliven Therapeutics Inc. stock gain from strong economy2025 Fundamental Recap & Weekly Breakout Watchlists - BỘ NỘI VỤ
Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect? - MSN
(ELVN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Enliven Therapeutics Inc (ELVN) is looking forward to a strong quarter - Setenews
Enliven Therapeutics targets CML drug resistance breakthrough - Traders Union
Enliven Therapeutics Insider Sold Shares Worth $279,155, According to a Recent SEC Filing - MarketScreener
Officer Lyssikatos Sells 12,500 ($279.2K) Of Enliven Therapeutics Inc [ELVN] - TradingView
[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity - Stock Titan
Will Enliven Therapeutics Inc. stock outperform international peersWeekly Market Report & AI Enhanced Trade Execution Alerts - newser.com
How Enliven Therapeutics Inc. stock reacts to Fed rate cutsGlobal Markets & Daily Technical Forecast Reports - newser.com
Why Enliven Therapeutics Inc. stock is favored by pension fundsWall Street Watch & Low Drawdown Investment Ideas - newser.com
What hedge fund activity signals for Enliven Therapeutics Inc. stock2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Is Enliven Therapeutics Inc. stock positioned well for digital economyMarket Risk Analysis & Expert-Curated Trade Recommendations - newser.com
Is Enliven Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & AI Powered Market Entry Ideas - newser.com
Enliven Therapeutics CEO Kintz sells $272k in shares By Investing.com - Investing.com Canada
CEO Kintz Sells 12,500 ($272.7K) Of Enliven Therapeutics Inc [ELVN] - TradingView
Shareholder Lyssikatos Revocable Trust 12/15/11 Files To Sell 12,500 Of Enliven Therapeutics Inc [ELVN] - TradingView
What analyst consensus says on Enliven Therapeutics Inc. stockJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Enliven Therapeutics Inc (ELVN) can make a big difference with a little luck - Setenews
Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy - Seeking Alpha
Enliven Therapeutics (ELVN): Assessing Valuation Following ENABLE Trial Milestone and Renewed Analyst Optimism - sahmcapital.com
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):